Low circulating anti-Mullerian hormone and normal follicle stimulating hormone levels: Which prognosis in an IVF program?

被引:14
作者
Grzegorczyk-Martin, V. [1 ]
Khrouf, M. [1 ]
Bringer-Deutsch, S. [1 ]
Mayenga, J. -M. [1 ]
Kuski, O. [1 ]
Cohen-Bacrie, P. [2 ]
Benaim, J. -L. [3 ]
Belaisch-Allart, J. [1 ]
机构
[1] Ctr Hosp 4 Villes, Serv Gynecol Obstet & Med Reprod, F-92318 Sevres, France
[2] Lab Eylau, F-75016 Paris, France
[3] Lab Benaim, F-92140 Clamart, France
来源
GYNECOLOGIE OBSTETRIQUE & FERTILITE | 2012年 / 40卷 / 7-8期
关键词
Anti-Mullerian hormone; Follicle stimulating hormone; Ovarian response; In vitro fertilization; IN-VITRO FERTILIZATION; ASSISTED REPRODUCTIVE TECHNOLOGY; SERUM ANTIMULLERIAN-HORMONE; POOR OVARIAN RESPONSE; INHIBIN-B; RESERVE; PREDICTION; PREGNANCY; CYCLES; MARKER;
D O I
10.1016/j.gyobfe.2012.02.001
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective. - To evaluate the results of controlled ovarian hyperstimulation (COH) for IVF in patients with low anti-Mullerian hormone (AMH) and normal basal follicle stimulating hormone (FSH) and Estradiol levels (<= 50 pg/mL). Patients and methods. - A retrospective cohort study including 704 patients for whom AMH and FSH levels (measured between days 3 and 5 of the menstrual cycle) were available, is performed in the IVF center at the Sevres Hospital (France). Three groups are designed and analyzed: group 1 with AMH less or equal to 2 ng/mL and FSH less or equal to 10 mUl/mL (study group), Group 2 with AMH greater than 2 ng/mL and FSH less or equal to 10 mUl/mL (control group) and Group 3 with AMH less or equal to 2 ng/mL and FSH greater than 10 mUl/mL (group with decreased ovarian reserve). Results. - IVF outcome for patients from the study group is significantly worse than that of the second but not than that of the third group. In the first group, the number of retrieved oocytes, the number of total obtained embryos, the clinical pregnancy rate and the live birth rate are significantly lower than in the second group; moreover, there are more cancelled cycles because of poor response in the first group. There is no difference with the third group. Discussion and conclusions. - This study shows that women with a low baseline AMH have a similar response to COH to the poor responders patients with a decreased ovarian reserve revealed by an elevated FSH level. Thus, when a woman undergoing IVF cycle presents a low AMH, she might be considered as a poor responder patient regardless of the FSH level and, although the clinical pregnancy rate is not so disappointing (18%), the couple should be informed of a higher risk of cycle cancellation. (c) 2012 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:411 / 418
页数:8
相关论文
共 44 条
[1]   Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis [J].
Bancsi, LFJMM ;
Broekmans, FJM ;
Mol, BWJ ;
Habbema, JDF ;
Velde, ERT .
FERTILITY AND STERILITY, 2003, 79 (05) :1091-1100
[2]   Comparing anti-Mullerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function [J].
Barad, David H. ;
Weghofer, Andrea ;
Gleicher, Norbert .
FERTILITY AND STERILITY, 2009, 91 (04) :1553-1555
[3]   A systematic review of tests predicting ovarian reserve and IVF outcome [J].
Broekmans, F. J. ;
Kwee, J. ;
Hendriks, D. J. ;
Mol, B. W. ;
Lambalk, C. B. .
HUMAN REPRODUCTION UPDATE, 2006, 12 (06) :685-718
[4]   The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count [J].
Broer, Simtone L. ;
Mol, Ben Willem J. ;
Hendriks, Dave ;
Broekmans, Frank J. M. .
FERTILITY AND STERILITY, 2009, 91 (03) :705-714
[5]   The relationship between the endocrine characteristics and the regularity of menstrual cycles in the approach to menopause [J].
Burger, HG ;
Robertson, DM ;
Baksheev, L ;
Collins, A ;
Csemiczky, G ;
Landgren, BM .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (03) :267-274
[6]   Antimullerian hormone serum levels: a putative marker for ovarian aging [J].
de Vet, A ;
Laven, JSE ;
de Jong, FH ;
Themmen, APN ;
Fauser, BCJM .
FERTILITY AND STERILITY, 2002, 77 (02) :357-362
[7]   Regulation of ovarian function: the role of anti-Mullerian hormone [J].
Durlinger, ALL ;
Visser, JA ;
Themmen, APN .
REPRODUCTION, 2002, 124 (05) :601-609
[8]   Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome [J].
Eldar-Geva, T ;
Ben-Chetrit, A ;
Spitz, IM ;
Rabinowitz, R ;
Markowitz, E ;
Mimoni, T ;
Gal, M ;
Zylber-Haran, E ;
Margalioth, EJ .
HUMAN REPRODUCTION, 2005, 20 (11) :3178-3183
[9]   Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation [J].
Fanchin, R ;
Schonäuer, LM ;
Righini, C ;
Frydman, N ;
Frydman, R ;
Taieb, J .
HUMAN REPRODUCTION, 2003, 18 (02) :328-332
[10]   Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) [J].
Fauser, BCJM ;
Chang, J ;
Azziz, R ;
Legro, R ;
Dewailly, D ;
Franks, S ;
Tarlatzis, BC ;
Fauser, B ;
Balen, A ;
Bouchard, P ;
Dahlgren, E ;
Devoto, L ;
Diamanti, E ;
Dunaif, A ;
Filicori, M ;
Homburg, R ;
Ibanez, L ;
Laven, J ;
Magoffin, D ;
Nestler, J ;
Norman, RJ ;
Pasquali, R ;
Pugeat, M ;
Strauss, J ;
Tan, S ;
Taylor, A ;
Wild, R ;
Wild, S ;
Ehrmann, D ;
Lobo, R .
HUMAN REPRODUCTION, 2004, 19 (01) :41-47